Changes in depression symptom network structure following ketamine treatment in treatment-resistant depression.
J Affect Disord May 14, 2026 Joshua Curtiss, Laya Dasari, Julianne Origlio et al.
Major Depressive Disorder (MDD) affects millions globally, with approximately 30% of patients experiencing treatment-resistant depression (TRD). While ketamine has emerged as a rapid-acting intervention, response rates remain variable, underscoring the need to refine precision medicine approaches for ketamine treatment. Network theories of mental health disorders have been promoted as framework...